13F filerCIK 1061768 ↗
Baupost Group
You are looking at Q1 2019. See the latest, Q3 2026 →
Reported value
$11.90B
+3.3% on the quarter before
Positions
35
8 new, 10 sold out
Top 10
64.9%
of the value
Est. gain
+$1.19B
on stocks held all quarter
Est. return
+16.6%
on those stocks since Q4 2018
Positions as of Mar 31, 2019, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2018. Striped tiles are options.
Largest buys
Since Q4 2018, sized at quarter-end prices.
- Fox Corp~$1.00BNew, 0.0% → 8.4% of the portfolio+27,322,720 shares
- Celgene Corp~$377.4MNew, 0.0% → 3.2% of the portfolio+4,000,000 shares
- Ebay Inc~$307.7MAdded, 5.1% → 9.1% of the portfolio+8,286,000 shares
- Cbs Corp New~$284.9MAdded, 1.0% → 3.4% of the portfolio+5,994,957 shares
- Liberty Global Plc~$226.4MAdded, 5.3% → 8.0% of the portfolio+9,350,200 shares
- Takeda Pharmaceutical Co Ltd~$217.3MNew, 0.0% → 1.8% of the portfolio+10,669,021 shares
- Fox Corp~$203.8MNew, 0.0% → 1.7% of the portfolio+5,680,307 shares
- Bristol Myers Squibb Co~$190.8MNew, 0.0% → 1.6% of the portfolio+4,000,000 shares
- Pg&E Corp~$160.7MAdded, 3.2% → 3.7% of the portfolio+9,025,517 shares
- Mckesson Corp~$128.2MAdded, 1.6% → 2.8% of the portfolio+1,095,000 shares
Largest sells
Since Q4 2018, sized at quarter-end prices.
- Twenty First Centy Fox Inc~$2.47BSold out, 21.4% → 0.0% of the portfolio−51,281,167 shares
- Twenty First Centy Fox Inc~$814.2MSold out, 7.1% → 0.0% of the portfolio−17,040,922 shares
- Pioneer Nat Res Co~$380.4MCut, 5.1% → 2.6% of the portfolio−2,498,186 shares
- Cheniere Energy Inc~$107.9MCut, 7.3% → 7.2% of the portfolio−1,577,827 shares
- Ypf Sociedad Anonima~$80.3MSold out, 0.7% → 0.0% of the portfolio−6,000,000 shares
- Shire Plc~$80.1MSold out, 0.7% → 0.0% of the portfolio−460,473 shares
- Cardinal Health Inc~$65.5MSold out, 0.6% → 0.0% of the portfolio−1,467,652 shares
- Amc Entmt Hldgs Inc~$17.9MSold out, 0.2% → 0.0% of the portfolio−1,458,002 shares
- Sentinel Energy Svcs Inc~$16.5MSold out, 0.1% → 0.0% of the portfolio−1,600,000 shares
- Synchrony Finl~$9.3MCut, 3.0% → 3.8% of the portfolio−293,000 shares
Holdings
As of Mar 31, 2019; changes in shares since Dec 31, 2018.
| Holding | Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ebay IncCOM · shares +39% · price +32.3% | 9.1% | $1.09B | +$190.5M | ||||||
| Viasat IncCOM · shares 0% · price +31.5% | 8.9% | $1.06B | +$254.7M | ||||||
| Fox CorpCL A COM · shares New | 8.4% | $1.00B | — | ||||||
| Liberty Global PlcSHS CL C · shares +31% · price +17.3% | 8.0% | $946.4M | +$106.2M | ||||||
| Cheniere Energy IncCOM NEW · shares −11% · price +15.5% | 7.2% | $862.6M | +$115.7M | ||||||
| QorvoCOM · shares −0.9% · price +18.1% | 6.4% | $759.6M | +$116.5M | ||||||
| Allergan PlcSHS · shares +0.3% · price +9.5% | 5.9% | $698.3M | +$60.6M | ||||||
| Synchrony FinlCOM · shares −2.0% · price +36.0% | 3.8% | $454.9M | +$120.4M | ||||||
| Pg&E CorpCOM · shares +58% · price −25.1% | 3.7% | $436.1M | −$92.1M | ||||||
| Cbs Corp NewCL B · shares +235% · price +8.7% | 3.4% | $406.0M | +$9.7M | ||||||
| Celgene CorpCOM · shares New | 3.2% | $377.4M | — | ||||||
| Mckesson CorpCOM · shares +64% · price +6.0% | 2.8% | $329.5M | +$11.3M | ||||||
| TeslaNOTE 2.375% 3/1 · shares 0% · price −9.8% | 2.8% | $328.3M | — | ||||||
| Pioneer Nat Res CoCOM · shares −56% · price +15.8% | 2.6% | $304.8M | +$41.6M | ||||||
| Colony Cap Inc NewCL A COM · shares 0% · price +13.7% | 2.2% | $264.3M | +$31.8M | ||||||
| Atara Biotherapeutics IncCOM · shares +2.0% · price +14.4% | 2.1% | $253.6M | +$31.3M | ||||||
| Antero Res CorpCOM · shares 0% · price −6.0% | 2.1% | $252.4M | −$16.0M | ||||||
| Takeda Pharmaceutical Co LtdSPONSORED ADS · shares New | 1.8% | $217.3M | — | ||||||
| Theravance Biopharma IncCOM · shares 0% · price −11.4% | 1.8% | $211.0M | −$27.2M | ||||||
| Univar IncCOM · shares 0% · price +24.9% | 1.8% | $210.5M | +$42.0M | ||||||
| Fox CorpCL B COM · shares New | 1.7% | $203.8M | — | ||||||
| Akebia Therapeutics IncCOM · shares 0% · price +48.1% | 1.7% | $200.4M | +$65.1M | ||||||
| Amerisourcebergen CorpCOM · shares +19% · price +6.9% | 1.6% | $191.2M | +$10.3M | ||||||
| Bristol Myers Squibb CoCOM · shares New | 1.6% | $190.8M | — | ||||||
| Liberty Global PlcSHS CL A · shares 0% · price +16.8% | 1.0% | $123.5M | +$17.7M | ||||||
| Total 35 positions | 100% | $11.90B | +$1.19B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2018 to Q1 2019: 25 stocks held throughout, up $1.19B (+16.6%).
- Viasat Inc+$254.7M+31%
- Ebay Inc+$190.5M+32%
- Synchrony Finl+$120.4M+36%
- Qorvo+$116.5M+18%
- Cheniere Energy Inc+$115.7M+15%
- Antero Res Corp−$16.0M−6%
- Theravance Biopharma Inc−$27.2M−11%
- Pg&E Corp−$92.1M−25%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | $5.05B−7% | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | $5.42B+6% | SEC ↗ |
| Q1 2026 | May 14, 2026 | $5.12B−3% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $5.28B+10% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $4.79B+16% | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | $4.13B+18% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $3.50B+2% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $3.43B−2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $3.52B−3% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $3.63B−0% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $3.65B−20% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $4.59B−12% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $5.21B−7% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $5.61B−4% | SEC ↗ |
| Q1 2023 | May 12, 2023 | $5.85B−5% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $6.13B+6% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $5.79B−14% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $6.77B−27% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $9.30B−8% | SEC ↗ |
| Q4 2021 | Feb 11, 2022 | $10.13B−7% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $10.88B−12% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $12.33B−2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $12.56B+16% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $10.84B+17% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $9.25B+15% | SEC ↗ |
| Q2 2020 | Aug 13, 2020 | $8.01B+18% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $6.77B−25% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $9.06B+3% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $8.83B−20% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $11.05B−7% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $11.90B+3% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 | $11.52B−12% | SEC ↗ |
| Q3 2018 | Nov 15, 2018 (amended) | $13.06B+14% | SEC ↗ |
| Q2 2018 | Aug 13, 2018 | $11.44B+10% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $10.37B+3% | SEC ↗ |
| Q4 2017 | Feb 13, 2018 | $10.11B+26% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $8.02B−8% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $8.75B+3% | SEC ↗ |
| Q1 2017 | May 25, 2017 (amended) | $8.49B+11% | SEC ↗ |
| Q4 2016 | Feb 14, 2017 | $7.67B+9% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $7.04B−4% | SEC ↗ |
| Q2 2016 | Aug 12, 2016 | $7.37B+6% | SEC ↗ |
| Q1 2016 | May 13, 2016 | $6.92B | SEC ↗ |